Targeting platelet receptor function in thrombus formation: The risk of bleeding

Blood Reviews

Volumn 28, Issue 1, 2014, Pages 9-21

  Swieringa, Frauke ^a   Kuijpers, Marijke J E ^a   Heemskerk, Johan W M ^a   Van der Meijden, Paola E J ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Antiplatelet drugs; Bleeding; Cardiovascular disease; Platelets; Thrombus

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; ATOPAXAR; CANGRELOR; CLOPIDOGREL; COLLAGEN; FIBRINOGEN; GLYCOPROTEIN VI; LAMININ; PLACEBO; PRASUGREL; PROSTAGLANDIN; PROSTANOID RECEPTOR; PROTEINASE ACTIVATED RECEPTOR 1; PROTEINASE ACTIVATED RECEPTOR 3; PROTEINASE ACTIVATED RECEPTOR 4; PURINERGIC P2X1 RECEPTOR; PURINERGIC P2Y1 RECEPTOR; PURINERGIC P2Y12 RECEPTOR; SELEXIPAG; TERUTROBAN; THROMBIN; THROMBIN RECEPTOR; THROMBOCYTE RECEPTOR; THROMBOXANE; THROMBOXANE RECEPTOR; TICAGRELOR; VON WILLEBRAND FACTOR; VORAPAXAR;

ACUTE CORONARY SYNDROME; BLEEDING; BLEEDING TIME; BLOOD CLOTTING; BRAIN HEMORRHAGE; CARDIOVASCULAR DISEASE; EXPERIMENTAL THROMBOSIS; GASTROINTESTINAL SYMPTOM; GENE MUTATION; GLANZMANN DISEASE; HEMOSTASIS; HUMAN; KIDNEY FAILURE; LABORATORY TEST; LEUKOCYTE ADHESION DEFICIENCY; LIGHT TRANSMISSION AGGREGOMETRY; NONHUMAN; PLATELET AGGREGATION ASSAY; PLATELET REACTIVITY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOCYTE DYSFUNCTION; THROMBOEMBOLISM; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; VON WILLEBRAND DISEASE;

ANTIPLATELET DRUGS; BLEEDING; CARDIOVASCULAR DISEASE; PLATELETS; THROMBUS;

ANIMALS; BLOOD PLATELETS; HEMORRHAGE; HUMANS; MICE; RECEPTORS, CELL SURFACE; THROMBOSIS;

EID: 84895182511     PISSN: 0268960X     EISSN: 15321681     Source Type: Journal    
DOI: 10.1016/j.blre.2013.12.001     Document Type: Article

References (163)

1. Hayward C.P. Diagnostic evaluation of platelet function disorders. Blood Rev 2011, 25:169-173.
2. Mackman N. Triggers, targets and treatments of thrombosis. Nature 2008, 451:914-918.
3. Heemskerk J.W., Mattheij N.J., Cosemans J.M. Platelet-based coagulation: different populations, different functions. J Thromb Haemost 2013, 11:2-16.
4. Hemker H.C., Al Dieri R., Béguin S. Thrombin generation assays: accruing clinical relevance. Curr Opin Hematol 2005, 11:170-175.
5. Coughlin S.R. Protease-activated receptors in hemostasis, thrombosis and vascular biology. J Thromb Haemost 2005, 3:1800-1814.
6. Kim S., Foster C., Lecchi A., Quinton T.M., Prosser D.M., Jin J., et al. Protease-activated receptors 1 and 4 do not stimulate Gi signaling pathways in the absence of secreted ADP and cause human platelet aggregation independently of Gi signaling. Blood 2002, 99:3629-3636.
7. Nurden A., Nurden P. Advances in our understanding of the molecular basis of disorders of platelet function. J Thromb Haemost 2011, 9(Suppl. 1):76-91.
8. Weiss E.J., Hamilton J.R., Lease K.E., Coughlin S.R. Protection against thrombosis in mice lacking PAR3. Blood 2002, 100:3240-3244.
9. Hamilton J.R., Cornelissen I., Coughlin S.R. Impaired hemostasis and protection against thrombosis in protease-activated receptor 4-deficient mice is due to lack of thrombin signaling in platelets. J Thromb Haemost 2004, 2:1429-1435.
10. Vandendries E.R., Hamilton J.R., Coughlin S.R., Furie B., Furie B.C. Par4 is required for platelet thrombus propagation but not fibrin generation in a mouse model of thrombosis. Proc Natl Acad Sci U S A 2007, 104:288-292.
11. Tricoci P., Huang Z., Held C., Moliterno D.J., Armstrong P.W., Van de Werf F., et al. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med 2012, 366:20-33.
12. Morrow D.A., Braunwald E., Bonaca M.P., Ameriso S.F., Dalby A.J., Fish M.P., et al. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med 2012, 366:1404-1413.
13. Scirica B.M., Bonaca M.P., Braunwald E., De Ferrari G.M., Isaza D., Lewis B.S., et al. Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2 degrees P-TIMI 50 trial. Lancet 2012, 380:1317-1324.
14. O'Donoghue M.L., Bhatt D.L., Wiviott S.D., Goodman S.G., Fitzgerald D.J., Angiolillo D.J., et al. Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes: the lessons from antagonizing the cellular effects of thrombin-acute coronary syndromes trial. Circulation 2011, 123:1843-1853.
15. Van de Werf F. Inhibitors of the platelet thrombin receptor: will they live up to their promisesα. Circulation 2011, 123:1833-1835.
16. 2 receptor and a critical role for phosphoinositide 3-kinases. J Biol Chem 2003, 278:30725-30731.
17. Offermanns S. Activation of platelet function through G protein-coupled receptors. Circ Res 2006, 99:1293-1304.
18. Dawood B.B., Lowe G.C., Lordkipanidze M., Bem D., Daly M.E., Makris M., et al. Evaluation of participants with suspected heritable platelet function disorders including recommendation and validation of a streamlined agonist panel. Blood 2012, 120:5041-5049.
19. 2. J Clin Invest 1998, 102:1994-2001.
20. Lewis H.D., Davis J.W., Archibald D.G., Steinke W.E., Smitherman T.C., Doherty J.E., et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. N Engl J Med 1983, 309:396-403.
21. Cairns J.A., Gent M., Singer J., Finnie K.J., Froggatt G.M., Holder D.A., et al. Aspirin, sulfinpyrazone, or both in unstable angina. Results of a Canadian multicenter trial. N Engl J Med 1985, 313:1369-1375.
22. Awtry E.H., Loscalzo J. Aspirin. Circulation 2000, 101:1206-1218.
23. Floyd C.N., Ferro A. Mechanisms of aspirin resistance. Pharmacol Ther 2014, 141:69-78.
24. Olsen A.M., Gislason G.H., Fosbol E.L. Time-perspective in cardiovascular risk of NSAID use after first-time myocardial infarction. Curr Opin Cardiol 2013, 28:683-688.
25. Fiessinger J.N., Bounameaux H., Cairols M.A., Clement D.L., Coccheri S., Fletcher J.P., et al. Thromboxane antagonism with terutroban in peripheral arterial disease: the TAIPAD study. J Thromb Haemost 2010, 8:2369-2376.
26. Lesault P.F., Boyer L., Pelle G., Covali-Noroc A., Rideau D., Akakpo S., et al. Daily administration of the TP receptor antagonist terutroban improved endothelial function in high-cardiovascular-risk patients with atherosclerosis. Br J Clin Pharmacol 2011, 71:844-851.
27. Gachet C. P2 receptors, platelet function and pharmacological implications. Thromb Haemost 2008, 99:466-472.
28. 1 receptor-null mice. J Clin Invest 1999, 104:1731-1737.
29. 12 receptor for adenosine diphosphate: congenital and drug-induced defects. Blood 2011, 117:2102-2112.
30. Schoenwaelder S.M., Ono A., Sturgeon S., Chan M., Mangin P., Maxwell M.J., et al. Identification of a unique co-operative PI 3-kinase signaling mechanism regulating integrin αIIbβ3 adhesive function in platelets. J Biol Chem 2007, 282:28648-28658.
31. 2 generation mediated by Gi signalling pathways. Biochem J 2010, 429:369-377.
32. Cosemans J.M., Munnix I.C., Wetzker R., Heller R., Jackson S.P., Heemskerk J.W. Continuous signaling via PI3K isoforms beta and gamma is required for platelet ADP receptor function in dynamic thrombus stabilization. Blood 2006, 108:3045-3052.
33. 1-deficient mice. Nat Med 1999, 5:1199-1202.
34. 1 receptor induces platelet hyper-reactivity in transgenic mice. J Thromb Haemost 2003, 1:155-163.
35. Hollopeter G., Jantzen H.M., Vincent D., Li G., England L., Ramakrishnan V., et al. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 2001, 409:202-207.
36. 2 and GPVI receptors. Hämostaseologie 2010, 30:29-38.
37. 12 regulates platelet adhesion/activation, thrombus growth, and thrombus stability in injured arteries. J Clin Invest 2003, 112:398-406.
38. 12. J Thromb Haemost 2012, 10:2149-2157.
39. Snoep J.D., Hovens M.M., Eikenboom J.C., van der Bom J.G., Jukema J.W., Huisman M.V. Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis. Am Heart J 2007, 154:221-231.
40. Gorgi M.A., Cohen-Arazi H., Gonzalez C.D., Di Girolamo G. Beyond efficacy: pharmacokinetic differences between clopidogrel, prasugrel and ticagrelor. Expert Opin Pharmacother 2011, 12:1285-1295.
41. Roberts J.D., Wells G.A., Le May M.R., Labinaz M., Glover C., Froeschl M., et al. Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial. Lancet 2012, 379:1705-1711.
42. 12 receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur Heart J 2008, 29:21-30.
43. Pandit A., Aryal M.R., Pandit A.A., Jalota L., Hakim F.A., Mookadam F., et al. Cangrelor versus clopidogrel in percutaneous coronary intervention: a systematic review and meta-analysis. EuroIntervention 2013, [in press].
44. 2+ in the human platelet. J Thromb Haemost 2007, 5:910-917.
45. 1 receptor due to deletion of a single amino acid residue. J Biol Chem 2000, 275:22611-22614.
46. 1 receptors. Nature 2000, 403:86-89.
47. 1 cation channel in thrombosis of small arteries in vivo. J Exp Med 2003, 198:661-667.
48. Mustard J.F., Kinlough-Rathbone R.L., Packham M.A. Prostaglandins and platelets. Annu Rev Med 1980, 31:89-96.
49. Gegenbauer K., Elia G., Blanco-Fernandez A., Smolenski A. Regulator of G-protein signaling 18 integrates activating and inhibiting signaling in platelets. Blood 2012, 119:3799-3807.
50. Subramanian H., Zahedi R.P., Sickmann A., Walter U., Gambaryan S. Phosphorylation of CalDAG-GEFI by protein kinase A prevents Rap1b activation. J Thromb Haemost 2013, 11:1574-1582.
51. Murata T., Ushikubi F., Matsuoka T., Hirata M., Yamasaki A., Sugimoto Y., et al. Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. Nature 1997, 388:678-682.
52. Stitham J., Arehart E., Elderon L., Gleim S.R., Douville K., Kasza Z., et al. Comprehensive biochemical analysis of rare prostacyclin receptor variants: study of association of signaling with coronary artery obstruction. J Biol Chem 2011, 286:7060-7069.
53. Petrucci G., De Cristofaro R., Rutella S., Ranelletti F.O., Pocaterra D., Lancellotti S., et al. Prostaglandin E2 differentially modulates human platelet function through the prostanoid EP2 and EP3 receptors. J Pharmacol Exp Ther 2011, 336:391-402.
54. 2 on human platelet function. Platelets 2010, 21:329-342.
55. Philipose S., Konya V., Sreckovic I., Marsche G., Lippe I.T., Peskar B.A., et al. The prostaglandin E2 receptor EP4 is expressed by human platelets and potently inhibits platelet aggregation and thrombus formation. Arterioscler Thromb Vasc Biol 2010, 30:2416-2423.
56. Heptinstall S., Espinosa D.I., Manolopoulos P., Glenn J.R., White A.E., Johnson A., et al. DG-041 inhibits the EP3 prostanoid receptor: a new target for inhibition of platelet function in atherothrombotic disease. Platelets 2008, 19:605-613.
57. 2 are novel antiplatelet agents that do not prolong bleeding. ACS Chem Biol 2009, 4:115-126.
58. 12 antagonist both in-vitro and ex-vivo in human volunteers. Platelets 2013, 24:392-400.
59. De Ceunynck K., De Meyer S.F., Vanhoorelbeke K. Unwinding the von Willebrand factor strings puzzle. Blood 2013, 121:270-277.
60. Yago T., Lou J., Wu T., Yang J., Miner J.J., Coburn L., et al. Platelet glycoprotein Ibalpha forms catch bonds with human WT vWF but not with type 2B von Willebrand disease vWF. J Clin Invest 2008, 118:3195-3207.
61. Ruggeri Z.M. The role of von Willebrand factor in thrombus formation. Thromb Res 2007, 120:S5-S9.
62. Auger J.M., Kuijpers M.J., Senis Y.A., Watson S.P., Heemskerk J.W. Adhesion of human and mouse platelets to collagen under shear: a unifying model. FASEB J 2005, 19:825-827.
63. Nesbitt W.S., Westein E., Tovar-Lopez F.J., Tolouei E., Mitchell A., Fu J., et al. A shear gradient-dependent platelet aggregation mechanism drives thrombus formation. Nat Med 2009, 15:665-673.
64. Westein E., van der Meer A.D., Kuijpers M.J., Frimat J.P., van den Berg A., Heemskerk J.W. Atherosclerotic geometries spatially confine and exacerbate pathological thrombus formation poststenosis in a von Willebrand factor-dependent manner. Proc Natl Acad Sci U S A 2013, 110:1357-1362.
65. Kasirer-Friede A., Cozzi M.R., Mazzucato M., De Marco L., Ruggeri Z.M., Shattil S.J. Signaling through GPIb/V/IX activates αIIbβ3 independently of other receptors. Blood 2004, 103:3403-3411.
66. Du X. Signaling and regulation of the platelet glycoprotein Ib-V-IX complex. Curr Opin Hematol 2007, 14:262-269.
67. 2 and FcγIIA receptor. J Biol Chem 2001, 276:26022-26029.
68. De Candia E., Hall S.W., Rutella S., Landolfi R., Andrews R.K., De Cristofaro R. Binding of thrombin to glycoprotein Ib accelerates the hydrolysis of PAR1 on intact platelets. J Biol Chem 2001, 276:4692-4698.
69. Cosemans J.M., Schols S.E., Stefanini L., de Witt S., Feijge M.A., Hamulyak K., et al. Key role of glycoprotein Ib/V/IX and von Willebrand factor in platelet activation-dependent fibrin formation at low shear flow. Blood 2011, 117:651-660.
70. Bergmeier W., Chauhan A.K., Wagner D.D. Glycoprotein Ibα and von Willebrand factor in primary platelet adhesion and thrombus formation: lessons from mice. Thromb Haemost 2008, 99:264-270.
71. Lenting P.J., Casari C., Christohpe O.D., Denis C.V. Von Willebrand factor: the old, the new and the unknown. J Thromb Haemost 2012, 10:2428-2437.
72. Ware J., Russell S., Ruggeri Z.M. Generation and rescue of a murine model of platelet dysfunction: the Bernard-Soulier syndrome. Proc Natl Acad Sci U S A 2000, 97:2803-2808.
73. Kato K., Martinez C., Russell S., Nurden P., Nurden A., Fiering S., et al. Genetic deletion of mouse platelet glycoprotein Ibβ produces a Bernard-Soulier phenotype with increased α-granule size. Blood 2004, 104:2339-2344.
74. Ramakrishnan V., DeGuzman F., Bao M., Hall S.W., Leung L.L., Phillips D.R. A thrombin receptor function for platelet glycoprotein Ib/IX unmasked by cleavage of glycoprotein V. Proc Natl Acad Sci U S A 2001, 98:1823-1828.
75. Fontayne A., Meiring M., Lamprecht S., Roodt J., Demarsin E., Barbeaux P., et al. The humanized anti-glycoprotein Ib monoclonal antibody h6B4-Fab is a potent and safe antithrombotic in a high shear arterial thrombosis model in baboons. Thromb Haemost 2008, 100:670-677.
76. Wu D., Meiring M., Kotze H.F., Deckmyn H., Cauwenberghs N. Inhibition of platelet glycoprotein Ib, glycoprotein IIb/IIIa, or both by monoclonal antibodies prevents arterial thrombosis in baboons. Arterioscler Thromb Vasc Biol 2002, 22:323-328.
77. Lillicrap D. Von Willebrand disease: phenotype versus genotype, deficiency versus disease. Thromb Res 2007, 120:S11-S16.
78. Nieswandt B., Watson S.P. Platelet-collagen interaction: is GPVI the central receptorα. Blood 2003, 102:449-461.
79. Jung S.M., Moroi M., Soejima K., Nakagaki T., Miura Y., Berndt M.C., et al. Constitutive dimerization of glycoprotein VI (GPVI) in resting platelets is essential for binding to collagen and activation in flowing blood. J Biol Chem 2012, 287:30000-30013.
80. Munnix I.C., Kuijpers M.J., Auger J., Thomassen C.M., Panizzi P., van Zandvoort M.A., et al. Segregation of platelet aggregatory and procoagulant microdomains in thrombus formation: regulation by transient integrin activation. Arterioscler Thromb Vasc Biol 2007, 27:2484-2490.
81. Watson S.P., Auger J.M., McCarty O.J., Pearce A.C. GPVI and integrin αIIbβ3 signaling in platelets. J Thromb Haemost 2005, 3:1752-1762.
82. Stegner D., Nieswandt B. Platelet receptor signaling in thrombus formation. J Mol Med 2011, 89:109-121.
83. Senis Y.A. Protein-tyrosine phosphatases: a new frontier in platelet signal transduction. J Thromb Haemost 2013, 11:1800-1813.
84. Tomlinson M.G., Calaminus S.D., Berlanga O., Auger J.M., Bori-Sanz T., Meyaard L., et al. Collagen promotes sustained glycoprotein VI signaling in platelets and cell lines. J Thromb Haemost 2007, 5:2274-2283.
85. Gilio K., Munnix I.C., Mangin P., Cosemans J.M., Feijge M.A., van der Meijden P.E., et al. Non-redundant roles of phosphoinositide 3-kinase isoforms alpha and beta in glycoprotein VI-induced platelet signaling and thrombus formation. J Biol Chem 2009, 284:33750-33762.
86. Stefanini L., Roden R.C., Bergmeier W. CalDAG-GEFI is at the nexus of calcium-dependent platelet activation. Blood 2009, 114:2506-2514.
87. Heemskerk J.W., Harper M.T., Cosemans J.M., Poole A.W. Unravelling the different functions of protein kinase C isoforms in platelets. FEBS Lett 2011, 585:1711-1716.
88. Dütting S., Bender M., Nieswandt B. Platelet GPVI: a target for antithrombotic therapy. Trends Pharmacol Sci 2012, 33:583-590.
89. Schulte V., Rabie T., Prostredna M., Aktas B., Grüner S., Nieswandt B. Targeting of the collagen-binding site on glycoprotein VI is not essential for in vivo depletion of the receptor. Blood 2003, 101:3948-3952.
90. Kuijpers M.J.E., Gilio K., Reitsma S., Nergiz-Unal R., Prinzen L., Heeneman S., et al. Complementary roles of platelets and coagulation in thrombus formation on plaques acutely ruptured by targeted ultrasound treatment: a novel intravital model. J Thromb Haemost 2009, 7:152-161.
91. Dubois C., Panicot-Dubois L., Merrill-Skoloff G., Furie B., Furie B.C. Glycoprotein VI-dependent and -independent pathways of thrombus formation in vivo. Blood 2006, 107:3902-3906.
92. Hechler B., Nonne C., Eckly A., Magnenat S., Rinckel J.Y., Denis C.V., et al. Arterial thrombosis: relevance of a model with two levels of severity assessed by histologic, ultrastructural and functional characterization. J Thromb Haemost 2010, 8:173-184.
93. Zahid M., Mangin P., Loyau S., Hechler B., Billiald P., Gachet C., et al. The future of glycoprotein VI as an antithrombotic target. J Thromb Haemost 2012, 10:2418-2427.
94. Matus V., Valenzuela G., Sáez C.G., Hidalgo P., Lagos M., Aranda E., et al. An adenine insertion in exon 6 of human GP6 generates a truncated protein associated with a bleeding disorder in four Chilean families. J Thromb Haemost 2013, 11:1751-1759.
95. Jones C.I., Bray S., Garner S.F., Stephens J., de Bono B., Angenent W.G.J., et al. A functional genomics approach reveals novel quantitative trait loci associated with platelet signaling pathways. Blood 2009, 114:1405-1416.
96. Johnson A.D., Yanek L.R., Chen M.H., Faraday N., Larson M.G., Tofler G., et al. Genome-wide meta-analyses identifies seven loci associated with platelet aggregation in response to agonists. Nat Genet 2010, 42:608-613.
97. Nieswandt B., Brakebusch C., Bergmeier W., Schulte V., Bouvard D., Mokhtari-Nejad R., et al. Glycoprotein VI but not α2β1 integrin is essential for platelet interaction with collagen. EMBO J 2001, 20:2120-2130.
98. Kuijpers M.J., Schulte V., Bergmeier W., Lindhout T., Brakebusch C., Offermanns S., et al. Complementary roles of glycoprotein VI and alpha2beta1 integrin in collagen-induced thrombus formation in flowing whole blood ex vivo. FASEB J 2003, 17:685-687.
99. Munnix I.C., Strehl A., Kuijpers M.J., Auger J.M., van der Meijden P.E., van Zandvoort M.A., et al. The glycoprotein VI-phospholipase Cγ2 signaling pathway controls thrombus formation induced by collagen and tissue factor in vitro and in vivo. Arterioscler Thromb Vasc Biol 2005, 25:2673-2678.
100. Elvers M., Pozgaj R., Pleines I., May F., Kuijpers M.J., Heemskerk J.M., et al. Platelet hyperreactivity and a prothrombotic phenotype in mice with a gain-of-function mutation in phospholipase Cγ2. J Thromb Haemost 2010, 8:1353-1363.
101. Watson S.P., Herbert J.M., Pollitt A.Y. GPVI and CLEC-2 in hemostasis and vascular integrity. J Thromb Haemost 2010, 8:1456-1467.
102. Siljander P.R., Munnix I.C., Smethurst P.A., Deckmyn H., Lindhout T., Ouwehand W.H., et al. Platelet receptor interplay regulates collagen-induced thrombus formation in flowing human blood. Blood 2004, 103:1333-1341.
103. Lecut C., Schoolmeester A., Kuijpers M.J., Broers J.L.V., van Zandvoort M.A., Vanhoorelbeke K., et al. Principal role of glycoprotein VI in α2β1 and αIIbβ3 activation during collagen-induced thrombus formation. Arterioscler Thromb Vasc Biol 2004, 24:1727-1733.
104. Matsumoto Y., Takizawa H., Nakama K., Gong X., Yamada Y., Tandon N.N., et al. Ex vivo evaluation of anti-GPVI antibody in cynomolgus monkeys: dissociation between anti-platelet aggregatory effect and bleeding time. Thromb Haemost 2006, 96:167-175.
105. Massberg S., Konrad I., Bultmann A., Schulz C., Munch G., Peluso M., et al. Soluble glycoprotein VI dimer inhibits platelet adhesion and aggregation to the injured vessel wall in vivo. FASEB J 2004, 18:397-399.
106. Ungerer M., Rosport K., Bultmann A., Piechatzek R., Uhland K., Schlieper P., et al. Novel antiplatelet drug revacept (dimeric glycoprotein VI-Fc) specifically and efficiently inhibited collagen-induced platelet aggregation without affecting general hemostasis in humans. Circulation 2011, 123:1891-1899.
107. Suzuki-Inoue K., Inoue O., Ozaki Y. Novel platelet activation receptor CLEC-2: from discovery to prospects. J Thromb Haemost 2011, 9(Suppl. 1):44-55.
108. Navarro-Nunez L., Langan S.A., Nash G.B., Watson S.P. The physiological and pathophysiological roles of platelet CLEC-2. Thromb Haemost 2013, 109:991-998.
109. Parguina A.F., Alonso J., Rosa I., Velez P., Gonzalez-Lopez M.J., Guitian E., et al. A detailed proteomic analysis of rhodocytin-activated platelets reveals novel clues on the CLEC-2 signalosome: implications for CLEC-2 signaling regulation. Blood 2012, 120:e117-e126.
110. May F., Hagedorn I., Pleines I., Bender M., Vogtle T., Eble J., et al. CLEC-2 is an essential platelet-activating receptor in hemostasis and thrombosis. Blood 2009, 114:3464-3472.
111. Bender M., May F., Lorenz V., Thielmann I., Hagedorn I., Finney B.A., et al. Combined in vivo depletion of glycoprotein VI and C-type lectin-like receptor 2 severely compromises hemostasis and abrogates arterial thrombosis in mice. Arterioscler Thromb Vasc Biol 2013, 33:926-934.
112. Moser M., Nieswandt B., Ussar S., Pozgajova M., Fässler R. Kindlin-3 is essential for integrin activation and platelet aggregation. Nat Med 2008, 14:325-330.
113. Petrich B.G., Marchese P., Ruggeri Z.M., Spiess S., Weichert R.A., Ye F., et al. Talin is required for integrin-mediated platelet function in hemostasis and thrombosis. J Exp Med 2007, 204:3103-3111.
114. Nieswandt B., Varga-Szabo D., Elvers M. Integrins in platelet activation. J Thromb Haemost 2009, 7(Suppl. 1):206-209.
115. Shattil S.J. Signaling through platelet integrin αIIbβ3: inside-out, outside-in sideways. Thromb Haemost 1999, 82:318-325.
116. Van der Meijden P.E., Feijge M.A., Swieringa F., Gilio K., Nergiz-Unal R., Hamulyak K., et al. Key role of integrin αIIbβ3 signaling to Syk kinase in tissue factor-induced thrombin generation. Cell Mol Life Sci 2012, 69:3481-3492.
117. Nurden A.T., Fiore M., Nurden P., Pillois X. Glanzmann thrombasthenia: a review of ITGA2B and ITGB3 defects with emphasis on variants, phenotypic variability, and mouse models. Blood 2011, 118:5996-6005.
118. Hodivala-Dilke K.M., McHugh K.P., Tsakiris D.A., Rayburn H., Crowley D., Ullman-Cullere M., et al. Beta3-integrin-deficient mice are a model for Glanzmann thrombasthenia showing placental defects and reduced survival. J Clin Invest 1999, 103:229-238.
119. Tronik-Le Roux D., Roullot V., Poujol C., Kortulewski T., Nurden P., Marguerie G. Thrombasthenic mice generated by replacement of the integrin αIIb gene: demonstration that transcriptional activation of this megakaryocytic locus precedes lineage commitment. Blood 2000, 96:1399-1408.
120. Malinin N.L., Zhang L., Choi J., Ciocea A., Razorenova O., Ma Y.Q., et al. A point mutation in KINDLIN3 ablates activation of three integrin subfamilies in humans. Nat Med 2009, 15:313-318.
121. Svensson L., Howarth K., McDowall A., Patzak I., Evans R., Ussar S., et al. Leukocyte adhesion deficiency-III is caused by mutations in KINDLIN3 affecting integrin activation. Nat Med 2009, 15:306-312.
122. Leopold J.A. Small-molecule glycoprotein IIb/IIIa antagonists and bleeding risk in women. Too much of a good thingα. Circulation 2006, 114:1344-1346.
123. Muniz-Lozano A., Rollini F., Franchi F., Angiolillo D.J. Update on platelet glycoprotein IIb/IIIa inhibitors: recommendations for clinical practice. Ther Adv Cardiovasc Dis 2013, 7:197-213.
124. Armstrong P.C., Peter K. GPIIb/IIIa inhibitors: from bench to bedside and back to bench again. Thromb Haemost 2012, 107:808-814.
125. Van de Vijver E., de Cuyper I.M., Gerrits A.J., Verhoeven A.J., Seeger K., Gutierrez L., et al. Defects in Glanzmann thrombasthenia and LAD-III (LAD-1/v) syndrome: the role of integrin β1 and β3 in platelet adhesion to collagen. Blood 2012, 119:583-586.
126. 2. Thromb Haemost 2007, 98:1072-1080.
127. Chen J., Diacovo T.G., Grenache D.G., Santoro S.A., Zutter M.M. The α2 integrin subunit-deficient mouse: a multifaceted phenotype including defects of branching morphogenesis and hemostasis. Am J Pathol 2002, 161:337-344.
128. Grüner S., Prostredna M., Aktas B., Moers A., Schulte V., Krieg T., et al. Anti-glycoprotein VI treatment severely compromises hemostasis in mice with reduced α2β1 levels or concomitant aspirin therapy. Circulation 2004, 110:2946-2951.
129. Petzold T., Ruppert R., Pandey D., Barocke V., Meyer H., Lorenz M., et al. β1 integrin-mediated signals are required for platelet granule secretion and hemostasis in mouse. Blood 2013, 122:2723-2731.
130. Nieuwenhuis H.K., Akkerman J.W., Houdijk W.P., Sixma J.J. Human blood platelets showing no response to collagen fail to express surface glycoprotein Ia. Nature 1985, 318:470-472.
131. Kehrel B., Balleisen L., Kokott R., Mesters R., Stenzinger W., Clemetson K.J., et al. Deficiency of intact thrombospondin and membrane glycoprotein Ia in platelets with defective collagen-induced aggregation and spontaneous loss of disorder. Blood 1988, 71:1074-1078.
132. Schaff M., Tang C., Maurer E., Bourdon C., Receveru N., Eckly A., et al. Integrin α6β1 is the main receptor for vascular laminins and plays a role in platelet adhesion, activation, and arterial thrombosis. Circulation 2013, 128:541-552.
133. Versteeg H.H., Heemskerk J.W., Levi M., Reitsma P.H. New fundamentals in hemostasis. Physiol Rev 2013, 93:327-358.
134. Jackson S.P. The growing complexity of platelet aggregation. Blood 2007, 109:5087-5095.
135. Brass L.F., Wannemacher K.M., Ma P., Stalker T.J. Regulating thrombus growth and stability to achieve an optimal response to injury. J Thromb Haemost 2011, 9(Suppl. 1):66-75.
136. Cosemans J.M., Angelillo-Scherrer A., Mattheij N.J., Heemskerk J.W. The effects of arterial flow on platelet activation, thrombus growth, and stabilization. Cardiovasc Res 2013, 99:342-352.
137. Watson S.P., Lowe G.C., Lordkipanidze M., Morgan N.V. Genotyping and phenotyping of platelet function disorders. J Thromb Haemost 2013, 11(Suppl. 1):351-363.
138. Deppermann C., Cherpokova D., Nurden P., Schulz J.N., Thielmann I., Kraft P., et al. Gray platelet syndrome and defective thrombo-inflammation in Nbeal2-deficient mice. J Clin Invest 2013, [in press] http://dx.doi.org/10.1172/JCI69210.
139. Nylander S., Kull B., Björkman J.A., Ulvinge J.C., Oakes N., Emanuelsson B.M., et al. Human target validation of phosphoinositide 3-kinase (PI3K)β: effects on platelets and insulin sensitivity, using AZD6482 a novel PI3Kβ inhibitor. J Thromb Haemost 2012, 10:2127-2136.
140. Mauer A.C., Khazanov N.A., Levenkova N., Tian S., Barbour E.M., Khalida C., et al. Impact of sex, age, race, ethnicity and aspirin use on bleeding symptoms in healthy adults. J Thromb Haemost 2011, 9:100-108.
141. Rydz N., James P.D. The evolution and value of bleeding assessment tools. J Thromb Haemost 2013, [in press] http://dx.doi.org/10.1111/j.1538-7836.2012.04923.x.
142. Rodeghiero F., Tosetto A., Abshire T., Arnold D.M., Coller B., James P., et al. ISTH/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders. J Thromb Haemost 2010, 8:2063-2965.
143. Lowe G.C., Lordkipanidzé M., Watson S.P., UK GAPP study group Utility of the ISTH bleeding assessment tool in predicting platelet defects in participants with suspected inherited platelet function disorders. J Thromb Haemost 2013, 11:1663-1668.
144. Mehran R., Rao S.V., Bhatt D.L., Gibson C.M., Caixeta A., Eikelboom J., et al. Standardized bleeding definitions for cardiovascular clinical trials. Circulation 2011, 123:2736-2747.
145. Harrison P., Mackie I., Mumford A., Briggs C., Liesner R., Winter M., et al. Guidelines for the laboratory investigation of heritable disorders of platelet function. Br J Haematol 2011, 155:30-44.
146. Cattaneo M., Cerletti C., Harrison P., Hayward C.P., Kenny D., Nugent D., et al. Recommendations for the standardization of light transmission aggregometry: a consensus of the working party from the Platelet Physiology Subcommittee of SSC/ISTH. J Thromb Haemost 2013, [in press] http://dx.doi.org/10.1111/jth.12231.
147. Hayward C.P., Harrison P., Cattaneo M., Ortel T.L., Rao A.K. Platelet function analyzer (PFA)-100 closure time in the evaluation of platelet disorders and platelet function. J Thromb Haemost 2006, 4:312-319.
148. Sladky J.L., Klima J., Grooms L., Kerlin B.A., O'Brien S.H. The PFA-100 (R) does not predict delta-granule platelet storage pool deficiencies. Haemophilia 2012, 18:626-629.
149. Goodall A.H., Appleby J. Flow-cytometric analysis of platelet-membrane glycoprotein expression and platelet activation. Methods Mol Biol 2004, 272:225-253.
150. Fox S.C., May J.A., Shah A., Neubert U., Heptinstall S. Measurement of platelet P-selectin for remote testing of platelet function during treatment with clopidogrel and/or aspirin. Platelets 2009, 20:250-259.
151. Roest M., van Holten T., Remijn J. Platelet activation test in unprocessed blood to monitor platelet concentrates and whole blood of thrombocytopenic patients. Transfus Med Hemother 2013, 40:117-125.
152. Vanschoonbeek K., Feijge M.A., van Kampen R.J., Kenis H., Hemker H.C., Giesen P.L., et al. Initiating and potentiating roles of platelets in tissue factor-induced thrombin generation in the presence of plasma: subject-dependent variation in thrombogram characteristics. J Thromb Haemost 2004, 2:476-484.
153. Subcommittee on Control of Anticoagulation of the SSC of the ISTH Towards a recommendation for the standardization of the measurement of platelet-dependent thrombin generation. J Thromb Haemost 2011, 9:1859-1861.
154. Ninivaggi M., Apitz-Castro R., Dargaud Y., de Laat B., Hemker H.C., Lindhout T. Whole-blood thrombin generation monitored with a calibrated automated thrombogram-based assay. Clin Chem 2012, 58:1252-1259.
155. Berny M.A., Munnix I.C., Auger J.M., Schols S.E., Cosemans J.M., Panizzi P., et al. Spatial distribution of factor Xa, thrombin, and fibrin(ogen) on thrombi at venous shear. PLoS One 2010, 5:e10415.
156. Roest M., Reininger A., Zwaginga J.J., King M.R., Heemskerk J.W. Flow chamber-based assays to measure thrombus formation in vitro: requirements for standardization. J Thromb Haemost 2011, 9:2322-2324.
157. Van Kruchten R., Cosemans J.M., Heemskerk J.W. Measurement of whole blood thrombus formation using parallel-plate flow chambers: a practical guide. Platelets 2012, 23:229-242.
158. 12 inhibitors. Circulation 2010, 121:171-179.
159. Janssen P.W., ten Berg J.M. Platelet function testing and tailored antiplatelet therapy. J Cardiovasc Transl Res 2013, 6:316-328.
160. Tantry U.S., Bonello L., Aradi D., Price M.J., Jeong Y.H., Angiolillo D.J., et al. Consensus and update on the definition of on-treatment platelet reactivity to ADP associated with ischemia and bleeding. J Am Coll Cardiol 2013, 62:2261-2273.
161. Tantry U.S., Gurbel P.A. Assessment of oral antithrombotic therapy by platelet function testing. Nat Rev Cardiol 2011, 8:572-579.
162. Michelson A.D. Platelets 2007, Elsevier, Amsterdam.
163. Burkhart J.M., Vaudel M., Gambaryan S., Radau S., Walter U., Martens L., et al. The first comprehensive and quantitative analysis of human platelet protein composition allows the comparative analysis of structural and functional pathways. Blood 2012, 120:e73-e82.